Comparision of Piceid and Resveratrol in Antioxidation and Antiproliferation Activities In Vitro

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Su, Dan ^a   Cheng, Ying ^a   Liu, Miao ^a   Liu, Daozhou ^a   Cui, Han ^a   Zhang, Bangle ^a   Zhou, Siyuan ^a   Yang, Tiehong ^a   Mei, Qibing ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN PEROXIDE; HYDROXYL RADICAL; IRON; PHENANTHROLINE; PICEID; RESVERATROL;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL DAMAGE; CELL PROTECTION; CELL STRAIN HEPG2; CELL STRAIN MCF 7; CELL VIABILITY; CONCENTRATION RESPONSE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; OXIDATIVE STRESS; TANDEM MASS SPECTROMETRY;

ANTIOXIDANTS; CELL LINE, TUMOR; CELL PROLIFERATION; GLUCOSIDES; HEP G2 CELLS; HUMANS; STILBENES;

EID: 84872442625     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054505     Document Type: Article

References (57)

1. Chen LW, Wang YQ, Wei LC, Shi M, Chan YS, (2007) Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson's disease. CNS Neurol Disord Drug Targets 6: 273-281.
2. Wang Y, Xu H, Fu Q, Ma R, Xiang J, (2011) Protective effect of resveratrol derived from Polygonum cuspidatum and its liposomal form on nigral cells in parkinsonian rats. J Neurol Sci 304: 29-34.
3. Delmas D, Jannin B, Latruffe N, (2005) Resveratrol: preventing properties against vascular alterations and ageing. Mol Nutr Food Res 49: 377-395.
4. Delmas D, Lancon A, Colin D, Jannin B, Latruffe N, (2006) Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr Drug Targets 7: 423-442.
5. Wenzel E, Somoza V, (2005) Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 49: 472-481.
6. Wenzel E, Soldo T, Erbersdobler H, Somoza V, (2005) Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol Nutr Food Res 49: 482-494.
7. Walle T, (2011) Bioavailability of resveratrol. Ann N Y Acad Sci 1215: 9-15.
8. Osmond GW, Masko EM, Tyler DS, Freedland SJ, Pizzo S (2012) In vitro and in vivo evaluation of resveratrol and 3,5-dihydroxy-4'-acetoxy-trans-stilbene in the treatment of human prostate carcinoma and melanoma. J Surg Res. 2012 Mar 28. [Epub ahead of print].
9. Osmond GW, Augustine CK, Zipfel PA, Padussis J, Tyler DS, (2012) Enhancing melanoma treatment with resveratrol. J Surg Res 172: 109-115.
10. Baur JA, Sinclair DA, (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506.
11. Nakata R, Takahashi S, Inoue H, (2012) Recent advances in the study on resveratrol. Biol Pharm Bull 35: 273-279.
12. SX L, JL L, N Z, Z C, (2009) The amount of resveratrol and piceid in Polygonum cuspidatum were affected by different processing method. Chinese Traditional and Herbal Drugs 3: 469-471.
13. Regev-Shoshani G, Shoseyov O, Bilkis I, Kerem Z, (2003) Glycosylation of resveratrol protects it from enzymic oxidation. Biochem J 374: 157-163.
14. Soleas GJ, Goldberg DM, Grass L, Levesque M, Diamandis EP, (2001) Do wine polyphenols modulate p53 gene expression in human cancer cell lines? Clin Biochem 34: 415-420.
15. Chung MI, Teng CM, Cheng KL, Ko FN, Lin CN, (1992) An antiplatelet principle of Veratrum formosanum. Planta Med 58: 274-276.
16. Orsini F, Pelizzoni F, Verotta L, Aburjai T, Rogers CB, (1997) Isolation, synthesis, and antiplatelet aggregation activity of resveratrol 3-O-beta-D-glucopyranoside and related compounds. J Nat Prod 60: 1082-1087.
17. Brohan M, Jerkovic V, Collin S, (2011) Potentiality of red sorghum for producing stilbenoid-enriched beers with high antioxidant activity. J Agric Food Chem 59: 4088-4094.
18. Lanzilli G, Cottarelli A, Nicotera G, Guida S, Ravagnan G, et al. (2012) Antiinflammatory effect of resveratrol and polydatin by in vitro IL-17 modulation. Inflammation 35: 240-248.
19. Zhai L, Zhang P, Sun RY, Liu XY, Liu WG, et al. (2011) Cytoprotective effects of CSTMP, a novel stilbene derivative, against H2O2-induced oxidative stress in human endothelial cells. Pharmacol Rep 63: 1469-1480.
20. Maeda R, Noiri E, Isobe H, Homma T, Tanaka T, et al. (2008) A water-soluble fullerene vesicle alleviates angiotensin II-induced oxidative stress in human umbilical venous endothelial cells. Hypertens Res 31: 141-151.
21. Lancon A, Delmas D, Osman H, Thenot JP, Jannin B, et al. (2004) Human hepatic cell uptake of resveratrol: involvement of both passive diffusion and carrier-mediated process. Biochem Biophys Res Commun 316: 1132-1137.
22. Lancon A, Hanet N, Jannin B, Delmas D, Heydel JM, et al. (2007) Resveratrol in human hepatoma HepG2 cells: metabolism and inducibility of detoxifying enzymes. Drug Metab Dispos 35: 699-703.
23. Alkhalaf M, (2007) Resveratrol-induced growth inhibition in MDA-MB-231 breast cancer cells is associated with mitogen-activated protein kinase signaling and protein translation. Eur J Cancer Prev 16: 334-341.
24. Martowicz A, Spizzo G, Gastl G, Untergasser G, (2012) Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines. BMC Cancer 12: 501.
25. Pozo-Guisado E, Merino JM, Mulero-Navarro S, Lorenzo-Benayas MJ, Centeno F, et al. (2005) Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB. Int J Cancer 115: 74-84.
26. Ming J, Yaxin C, Jinrong L, Hui Z, (1996) 10-Phenanthroline-Fe2+ oxidative assay of hydroxyl radical produced by H2O2/Fe2+. Prog Biochem Biophys 23: 553-555.
27. Zhou S, Yang R, Teng Z, Zhang B, Hu Y, et al. (2009) Dose-dependent absorption and metabolism of trans-polydatin in rats. J Agric Food Chem 57: 4572-4579.
28. Marnett LJ, (2000) Oxyradicals and DNA damage. Carcinogenesis 21: 361-370.
29. Esterbauer H, Ramos P, (1996) Chemistry and pathophysiology of oxidation of LDL. Rev Physiol Biochem Pharmacol 127: 31-64.
30. Pintea A, Rugina D, Pop R, Bunea A, Socaciu C, et al. (2011) Antioxidant effect of trans-resveratrol in cultured human retinal pigment epithelial cells. J Ocul Pharmacol Ther 27: 315-321.
31. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220.
32. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, et al. (2004) Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24: 2783-2840.
33. Signorelli P, Ghidoni R, (2005) Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. The Journal of Nutritional Biochemistry 16: 449-466.
34. Monte SMdl, Luong T, Neely TR, Robinson D, Wands JR, (2000) Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease. Laboratory Investigation 80: 1323-1336.
35. Paulo M, Salvador MM, dos Anjos Neto Filho M, Montes MB, Franceschini SA, et al. (2009) Effect of isoflavone extracts from Glycine max on human endothelial cell damage and on nitric oxide production. Menopause 16: 539-544.
36. Russo GL, (2007) Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem Pharmacol 74: 533-544.
37. Mukherjee S, Dudley JI, Das DK, (2010) Dose-dependency of resveratrol in providing health benefits. Dose Response 8: 478-500.
38. Lee KW, Lee HJ, (2006) Biphasic effects of dietary antioxidants on oxidative stress-mediated carcinogenesis. Mech Ageing Dev 127: 424-431.
39. Elbling L, Weiss RM, Teufelhofer O, Uhl M, Knasmueller S, et al. (2005) Green tea extract and (-)-epigallocatechin-3-gallate, the major tea catechin, exert oxidant but lack antioxidant activities. FASEB J 19: 807-809.
40. Lambert JD, Elias RJ, (2010) The anti-oxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention. Arch Biochem Biophys 501: 65-72.
41. Stocco B, Toledo K, Salvador M, Paulo M, Koyama N, et al. (2012) Dose-dependent effect of resveratrol on bladder cancer cells: chemoprevention and oxidative stress. Maturitas 72: 72-78.
42. Bai Y, Mao QQ, Qin J, Zheng XY, Wang YB, et al. (2010) Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci 101: 488-493.
43. Shakibaei M, Harikumar KB, Aggarwal BB, (2009) Resveratrol addiction: to die or not to die. Mol Nutr Food Res 53: 115-128.
44. Kuwajerwala N, Cifuentes E, Gautam S, Menon M, Barrack ER, et al. (2002) Resveratrol induces prostate cancer cell entry into s phase and inhibits DNA synthesis. Cancer Res 62: 2488-2492.
45. Szende B, Tyihak E, Kiraly-Veghely Z, (2000) Dose-dependent effect of resveratrol on proliferation and apoptosis in endothelial and tumor cell cultures. Exp Mol Med 32: 88-92.
46. Das S, Das DK, (2007) Resveratrol: a therapeutic promise for cardiovascular diseases. Recent Pat Cardiovasc Drug Discov 2: 133-138.
47. Joe AK, Liu H, Suzui M, Vural ME, Xiao D, et al. (2002) Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res 8: 893-903.
48. Opipari AW Jr, Tan L, Boitano AE, Sorenson DR, Aurora A, et al. (2004) Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res 64: 696-703.
49. Goldberg DM, Yan J, Soleas GJ, (2003) Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 36: 79-87.
50. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK, (2004) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32: 1377-1382.
51. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, et al. (2007) Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16: 1246-1252.
52. Rathel TR, Samtleben R, Vollmar AM, Dirsch VM, (2007) Activation of endothelial nitric oxide synthase by red wine polyphenols: impact of grape cultivars, growing area and the vinification process. J Hypertens 25: 541-549.
53. Appeldoorn MM, Venema DP, Peters TH, Koenen ME, Arts IC, et al. (2009) Some phenolic compounds increase the nitric oxide level in endothelial cells in vitro. J Agric Food Chem 57: 7693-7699.
54. Kaldas MI, Walle UK, Walle T, (2003) Resveratrol transport and metabolism by human intestinal Caco-2 cells. J Pharm Pharmacol 55: 307-312.
55. van de Wetering K, Burkon A, Feddema W, Bot A, de Jonge H, et al. (2009) Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol. Mol Pharmacol 75: 876-885.
56. Alfaras I, Perez M, Juan ME, Merino G, Prieto JG, et al. (2010) Involvement of breast cancer resistance protein (BCRP1/ABCG2) in the bioavailability and tissue distribution of trans-resveratrol in knockout mice. J Agric Food Chem 58: 4523-4528.
57. Delmas D, Lin HY, (2011) Role of membrane dynamics processes and exogenous molecules in cellular resveratrol uptake: consequences in bioavailability and activities. Mol Nutr Food Res 55: 1142-1153.